Company intelligence / Profile preview
Silence Therapeutics
London, London, United Kingdomsilence-therapeutics.com ↗
- Ownership
- Public · SLN
- Employees
- ~116
- Development stage
- Phase 2
01
Overview
Phase 1 study of zerlasiran (SLN360) showed injection of repeated doses reduced patients' baseline of Lp(a) by up to 99 per cent for 90 days after administration
- Therapeutic areas
- Rare DiseasesHematologyGastroenterologyCardiovascular
- Modalities
- siRNA (short interfering RNA)RNA interference (RNAi)
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
AstraZeneca PLCMallinckrodt PharmaceuticalsHansoh Pharma
04
Financials
- Market cap
- $931.5M
- Total revenue
- $559K
- Enterprise value
- $859.5M
Beyond the preview
Go deeper on Silence Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Silence Therapeutics.